Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
← catalyst calendarNCT07486713 · readout in 254 d
Sponsored by Rigel Pharmaceuticals (industry) · RIGL — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
16estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-23 | actual | When the study began enrolling |
| Primary completion | 2027-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- AML (Acute Myeloid Leukemia)
- Glioma
- Cholangiocarcinoma
- Solid Tumor Malignancies
Interventions
- Drug: Olutasidenib
- Drug: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Primary outcomes
what the primary-completion date above is the date OFArea Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs
measured Up to 96 hours after each probe drug administration.
Maximum Plasma Concentration (Cmax) of Probe Drugs
measured Up to 96 hours after each probe drug administration.
Permalink · RIGL's whole pipeline · Catalyst calendar · Every registered study · What changed